Physician profile
Jonathan E Hickson
NPI 1285021881
$1,527.13
in general payments reported to CMS, 2019-2025
22 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.79 · 2024: $316 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.43 | 2025 | |
| Vanda Pharmaceuticals INC. | $218.09 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.77 | 2025 | Caplyta |
| Lilly USA, LLC | $92.31 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $76.95 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $76.70 | 2024-2025 | Airsupra, Farxiga |
| Lundbeck LLC | $63.92 | 2024 | Vyepti |
| Corium, LLC | $62.97 | 2025 | Azstarys |
| Abbott Laboratories | $59.44 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.48 | 2025 | Jascayd, Jardiance |
| Amgen INC. | $50.93 | 2025 | Otezla, Repatha |
| Dexcom, INC. | $45.03 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $37.43 | 2024-2025 | Auvelity |
| Optinose US, INC. | $36.50 | 2025 | |
| Alkermes, INC. | $34.89 | 2025 | Aristada, Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.62 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $33.09 | 2024 | Quviviq |
| Novo Nordisk INC | $31.82 | 2024-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $27.82 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $21.19 | 2025 | Spravato |
| Genentech USA, INC. | $20.79 | 2020 | |
| Exact Sciences Corporation | $18.96 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.